Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Pro Medicus (ASX:PME) share price falls despite new $31 million win

The Pro Medicus Ltd (ASX:PME) share price went down 3% despite announcing a new contract win. 

The Pro Medicus Ltd (ASX: PME) share price went down 3% despite announcing a new contract win.

What was the Pro Medicus new win?

Pro Medicus revealed that it has signed a 7-year $31 million deal with a major academic health system comprising UC Los Angeles (UCLA), UC San Francisco (UCSF), UC San Diego (UCSD), UC Davis (UCD) and UC Irvine (UCI).

The contract, based on a transactional licensing model, will see the company’s Visage 7 Viewer implemented across the five diagnostic imaging departments, the first time the entire system will be unified on a single diagnostic imaging platform.

Pro Medicus’ deal also provides the option for the health system’s affiliates to standardise on the Visage platform providing potential upside in addition to that provided by the transaction-based model.

Planning for the rollout is to commence immediately with initial ‘go lives’ targeted for the second half of the calendar year with all campuses to be deployed over an 18 to 24 month period.

Pro Medicus was very pleased with this deal because it further extends its footprint in tier 1 academic health systems.

Pro Medicus management comments

Dr Sam Hupert, the CEO of Pro Medicus, said: “This was a highly sought after, extremely competitive tender and as you would expect for such a large and highly sophisticated client, they underwent a very extensive evaluation process that included onsite pilots involve all five main campuses. The fact we won unanimous endorsement speaks to the strength of our offering.”

Time to buy Pro Medicus shares?

The ASX medical technology business has won six out of six of the major contracts in the market over the last seven months, across a broad range of opportunities in the US and Europe.

With such a high EBIT margin (EBIT explained), a lot of this new revenue will fall to the bottom line of Pro Medicus – which is great for profit growth. It’s a high quality business, with no debt, a growing cash balance and a rising dividend.

However, the Pro Medicus share price has almost doubled over the last year and it’s now valued at 162 times the estimated earnings for the 2021 financial year, according to CommSec. That’s very expensive, even for a high quality business like this one.

There are probably a few other ASX tech shares I’d rather invest in first, but if I were already a Pro Medicus shareholder I’d be happy today.

Before you consider Pro Medicus, I suggest getting a free Rask account and accessing our full stock reports. Click this link to join for free and access our analyst reports.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content